NEW YORK (GenomeWeb) – A new study has confirmed that a biomarker suspected from earlier studies to be associated with response to the EGFR inhibitor cetuximab (Erbitux) does indeed appear to predict which KRAS wild-type colorectal cancer patients are more or less likely to respond to the drug.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.